Associated tags: Cardinal Health, Health, CAH, NYSE, Patient
Locations: NEW YORK, UNITED STATES, SEARS, EUROPE, MIDDLE EAST, SOUTH AMERICA, TEXAS, CAROLINAS, LATIN AMERICA, PUERTO RICO, CALIFORNIA, ALABAMA, VIRGINIA, ROCKVILLE, MD, LONDON, SOUTH CAROLINA, OHIO, MISSOURI, LOUISIANA, TENNESSEE, GEORGIA
COLUMBUS, Ohio, April 2, 2024 /PRNewswire/ -- Today, Cardinal Health (NYSE: CAH) announced that construction has begun for a new 350,000 square-foot logistics center in Columbus, Ohio, that will serve as a centralized replenishment center for the distribution of over-the-counter consumer health products in support of its core pharmaceutical business.
Key Points:
- COLUMBUS, Ohio, April 2, 2024 /PRNewswire/ -- Today, Cardinal Health (NYSE: CAH) announced that construction has begun for a new 350,000 square-foot logistics center in Columbus, Ohio, that will serve as a centralized replenishment center for the distribution of over-the-counter consumer health products in support of its core pharmaceutical business.
- Located in the Rickenbacker Global Logistics Park, the Consumer Health Logistics Center will be the fourth Cardinal Health distribution facility in Central Ohio, along with its corporate headquarters in Dublin, Ohio.
- "Over the past five years, we've seen rapid growth in the demand for consumer health products," said Debbie Weitzman, CEO Pharmaceutical & Specialty Solutions.
- "The innovative technology and solutions powering the Consumer Health Logistics Center will be a differentiator in the marketplace," stated Jamie Barker, SVP, Pharmaceutical Supply Chain.
DUBLIN, Ohio, March 26, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release third-quarter financial results for its fiscal year 2024 on May 2, prior to the opening of trading on the New York Stock Exchange.
Key Points:
- DUBLIN, Ohio, March 26, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release third-quarter financial results for its fiscal year 2024 on May 2, prior to the opening of trading on the New York Stock Exchange.
- The company will webcast a discussion of these results beginning at 8:30 a.m. Eastern.
- To access the webcast and corresponding slide presentation, visit Cardinal Health's Investor Relations page.
- Presentation slides and a webcast replay will be available on the Investor Relations page for 12 months.
CDP,
Climate change,
WWF,
Science Based Targets initiative,
Environment,
Carbon accounting,
World Resources Institute,
GHG,
Cardinal Health,
ESG,
Science,
United Nations Global Compact,
Social,
CAH,
Targets,
WRI,
Renewable energy Targets are considered science-based if they align with what the latest climate science says is necessary to limit global warming to 1.5°C above pre-industrial levels.
Key Points:
- Targets are considered science-based if they align with what the latest climate science says is necessary to limit global warming to 1.5°C above pre-industrial levels.
- "As we work to achieve our targets, we will collaborate with partners along our supply chain to collectively address the impacts of climate change," Maltenfort said.
- By the end of fiscal 2023, Cardinal Health had reduced its Scope 1 and 2 emissions by 13% from a fiscal 2019 base year.
- Cardinal Health reports on progress toward its climate goals in its annual Environmental, Social and Governance (ESG) Report.
Retrieved on:
Thursday, February 29, 2024
DUBLIN, Ohio, Feb. 29, 2024 /PRNewswire/ -- Today, Cardinal Health (NYSE: CAH) released its 2024 Biosimilars Report: insights on a pivotal year of evolution and expansion, an analysis of key recent economic, competitive, legislative and societal developments in biosimilars. The publication highlights legislative developments and new treatments, including adalimumab biosimilars. The report also provides the perspectives of retina specialists on biosimilars, ahead of the expected launch of multiple new biosimilars for retinal diseases.
Key Points:
- DUBLIN, Ohio, Feb. 29, 2024 /PRNewswire/ -- Today, Cardinal Health (NYSE: CAH) released its 2024 Biosimilars Report: insights on a pivotal year of evolution and expansion, an analysis of key recent economic, competitive, legislative and societal developments in biosimilars.
- The report also provides the perspectives of retina specialists on biosimilars, ahead of the expected launch of multiple new biosimilars for retinal diseases.
- The report examines a year of major developments in biosimilars, offering expert commentary and provider perspectives on a rapidly changing industry landscape.
- With 2024 expected to be a critical year for retina biosimilars, Cardinal Health surveyed providers in ophthalmology to obtain perspectives that may influence adoption while highlighting continued obstacles to wider use of biosimilars.
Retrieved on:
Wednesday, February 28, 2024
Amgen,
Cardinal Health,
MBA,
ADC,
Juno Therapeutics,
University,
Therapy,
Organization,
CAH,
Harvard Business School,
Religious studies,
Clovis Oncology,
Lundbeck Seattle Biopharmaceuticals,
Management DUBLIN, Ohio, Feb. 28, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors has elected Robert "Bob" Azelby as an independent director, effective March 1.
Key Points:
- DUBLIN, Ohio, Feb. 28, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors has elected Robert "Bob" Azelby as an independent director, effective March 1.
- Mr. Azelby joins the board with over 30 years of experience, including as a Chief Executive Officer and board member for large, matrixed organizations in the biopharmaceutical, oncology and other specialty industries.
- Mr. Azelby currently serves on the Boards of Directors of ADC Therapeutics and Autolus Therapeutics.
- "Bob Azelby is a highly respected healthcare industry leader with a strong track record of leading large, complex organizations as both a CEO and a board member," said Greg Kenny, Chairman of the Board for Cardinal Health.
Retrieved on:
Monday, February 12, 2024
Cardinal,
Hospital,
POC,
FDA,
Infection,
Female,
Pharmacy,
Cardinal Health,
Emergency,
World Congress,
Patient,
CLIA,
Diagnosis,
Male,
Gonorrhea,
Chlamydia,
STI,
Medical imaging Collaborating with Cardinal Health provides binx health with additional access to the acute clinical care settings via its vast sales network in the market.
Key Points:
- Collaborating with Cardinal Health provides binx health with additional access to the acute clinical care settings via its vast sales network in the market.
- We are proud that we have earned their trust in binx and the binx io," said Jeffrey Luber, binx health’s Chief Executive Officer.
- With this distribution collaboration, together binx health and Cardinal Health teams will help improve access to the treatment of CT/NG.
- For more information about the binx io, visit mybinxhealth.com/binx-io or contact your Cardinal Health representative.
Retrieved on:
Tuesday, February 6, 2024
NEW HAVEN, Conn., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces it has entered into a distribution agreement with Cardinal Health for its HemeScreen molecular assay products.
Key Points:
- NEW HAVEN, Conn., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces it has entered into a distribution agreement with Cardinal Health for its HemeScreen molecular assay products.
- Under the agreement, Cardinal Health will market and distribute Precipio’s HemeScreen portfolio of molecular assays to its customer base, which comprises primarily the acute healthcare systems (hospital networks), as well as reference laboratories and physician owned laboratories.
- “The addition of this agreement with Cardinal Health, and alongside distribution agreements Precipio has with Fisher Healthcare and McKesson, strengthens our distribution network and positions us for growth in 2024”, said Ilan Danieli, Precipio’s CEO.
- “Cardinal Health is a formidable player in the market, and we are excited to work with them to deliver value to their customers, and to the patients they serve”.
Retrieved on:
Tuesday, February 6, 2024
Science Based Targets initiative,
ESG,
GRI,
Task force,
TCFD,
Cardinal Health,
Social,
Prevalence,
Patient,
GHG,
Carbon,
Sustainability,
Sustainability accounting,
Targets,
SBT,
Science,
CAH,
Workforce,
Organization,
LCA DUBLIN, Ohio, Feb. 6, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today released its Fiscal 2023 Environmental, Social and Governance (ESG) Report , highlighting the company's work toward building a healthier, more equitable future.
Key Points:
- DUBLIN, Ohio, Feb. 6, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today released its Fiscal 2023 Environmental, Social and Governance (ESG) Report , highlighting the company's work toward building a healthier, more equitable future.
- Cardinal Health enhanced efforts to reduce mental health stigma and increase employees' access to services to support mental well-being.
- Cardinal Health reduced its Scope 1 and Scope 2 greenhouse gas (GHG) emissions by 13%i, from a fiscal 2019 base year, making progress toward its fiscal 2030 50% reduction goal.
- Please view the full Cardinal Health Fiscal 2023 ESG Report here: CardinalHealth.com/ESGReport .
Retrieved on:
Wednesday, January 31, 2024
Partnership,
Practice management,
EMR,
Growth,
Research,
Cardinal Health,
Natural language processing,
Patient,
Medication,
Cardinal,
Artificial intelligence,
Physician,
GPO,
CAH,
Acquisition,
Eurosport 1,
Nursing Specialty Networks creates clinical and economic value for independent specialty providers and partners across multiple specialty GPOs: UroGPO, Gastrologix and GastroGPO, and United Rheumatology.
Key Points:
- Specialty Networks creates clinical and economic value for independent specialty providers and partners across multiple specialty GPOs: UroGPO, Gastrologix and GastroGPO, and United Rheumatology.
- "Expanding in specialty is a top priority for us and we have been investing to expand our offering," said Jason Hollar, CEO Cardinal Health.
- "Specialty Networks is a leader in specialty practice management, research and technologies that support physicians in delivering best-in-class care to their patients," said Debbie Weitzman, CEO, Cardinal Health Pharmaceutical and Specialty Solutions.
- Through its Specialty business, Cardinal Health provides reliable distribution and advanced technology solutions to community-based practices across the nation.
Cardinal,
Cardinal Health,
Medication,
Share repurchase,
Element,
Logistics,
Investment,
EPS,
Mason,
Medicine,
Calendar,
Health,
Robotics,
Transport,
CAH,
Growth "We are excited to demonstrate further progress on how we are driving our company, and healthcare, forward," said Jason Hollar CEO of Cardinal Health.
Key Points:
- "We are excited to demonstrate further progress on how we are driving our company, and healthcare, forward," said Jason Hollar CEO of Cardinal Health.
- We continue to prioritize focused execution to best serve our customers and advance our mission as healthcare's most trusted partner."
- This conclusion follows the June 2023 announcement that the business review determined that Cardinal Health would retain and invest in its attractive Nuclear and Precision Health Solutions business.
- The company updated fiscal year 2024 non-GAAP diluted EPS guidance to the high end of its $6.75 to $7.00 range.
